---
schema_version: "secwatch.filing_event.v1"
accession: "0000805928-26-000004"
form_type: "8-K"
ticker: "AXGN"
cik: "0000805928"
company_name: "Axogen, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:59:27.429390+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Axogen reports preliminary Q4 revenue $59.9M (+21.3% YoY); full-year $225.2M (+20.2%); FDA BLA approval for Avance

## Summary
- Q4 2025 revenue ~$59.9M (+21.3% YoY); full-year 2025 revenue ~$225.2M (+20.2% YoY).
- Gross margin expected above 74% for Q4 and FY 2025; includes ~$1.9M one-time costs related to Avance BLA approval, 67% non-cash.
- Cash, equivalents, restricted cash, and investments ~$45.5M at Dec 31, 2025, up ~$6.0M from end of 2024.
- FDA approved Biologics License Application for Avance (acellular nerve allograft) on Dec 3, 2025.
- Growth driven by commercial strategy targeting Extremities and OMF-Head & Neck, and increased Resensation penetration.

## SEC filing metadata
- accession: 0000805928-26-000004
- form_type: 8-K
- ticker: AXGN
- cik: 0000805928
- company_name: Axogen, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/805928/000080592826000004/0000805928-26-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/805928/000080592826000004/axgn-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000805928-26-000004
- JSON: https://secwatch.observer/filing/0000805928-26-000004.json
- Plain text: https://secwatch.observer/filing/0000805928-26-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.